Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Inks UK Distribution Deal for Prostate Cancer Test

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a UK distribution agreement for its SelectMDx prostate cancer test with Lab21.

Under the terms of the deal, Lab21 will serve as a non-exclusive distributor of the test in the UK, and send liquid biopsy samples to MDxHealth's clinical diagnostic lab in The Netherlands for analysis. Lab21 will reimburse MDxHealth for all testing services performed.

Additional terms were not disclosed.

"In the UK, about 40,000 men a year undergo an unnecessary prostate biopsy and risk its associated complications," MDxHealth CEO Jan Groen said in a statement. "Lab21 is the ideal partner to bring SelectMDx to UK physicians and patients for the first time."

The agreement with Lab21 marks the latest in a series of distribution arrangements MDxHealth has struck recently for SelectMDx including ones covering Hong Kong and Macao, Central and South America, Poland, and Israel.